Feed / MIR

Mirion Technologies, Inc.

MIR

Industrials · 15.84 -4.8% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Mirion Technologies, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.

Company-4.8% todayVolume comparison unavailable
Market group0 of 1 activeRadiation Detection & Safety · unavailable
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
  • MIR's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if MIR's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Industrials · Specialty Industrial Machinery

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • MIR's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods7
Price observations327
Usable filing statements123
Verified relationships5
Evidence supporting the case
  • Latest annual revenue changed +7.5% year over year.
  • Operating margin changed +2.7 percentage points in the latest annual period.
  • Net margin changed +7.3 percentage points in the latest annual period.
  • Operating cash flow covered net income at 4.98x in the latest annual period.
  • Foreign exchange has repeated favorable evidence across 4 filings.
  • Macroeconomic conditions has repeated favorable evidence across 4 filings.
  • Pricing and mix has repeated favorable evidence across 4 filings.
Evidence challenging the case
  • Diluted shares increased 27.4% in the latest annual period.
Questions before a position
  • EV/sales is 83% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

15.84
6m-26.7%12m-28.3%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-06-30$611.6M+27.9%$-24.18+1.5%
2022-12-31$717.8M+17.4%$-1.53
2023-12-31$800.9M+11.6%$-0.49+8.4%
2024-12-31$860.8M+7.5%$-0.18+4.4%
2025-12-31$925.4M+7.5%$0.11+27.4%

What management says matters

Persistent and emerging business drivers

Foreign exchangepositive · 4 filings
Medical Unaudited (In millions) Three Months Ended March 31, 2026 Three Months Ended March 31, 2025 Revenues $ 72.1 $ 68.6 Income from operations $ 7.8 $ 6.7 Income from operations as a % of revenues 10.8 % 9.8 % 49 Table of Content s Medical segment revenues…
10-Q · Apr 29, 2026
Legal and regulatory exposuremixed · 4 filings
This agreement was fully executed in March 2026 after the obtainment of customary performance guarantees (which had been previously delayed due to certain Russian sanctions).
10-Q · Apr 29, 2026
Macroeconomic conditionsmixed · 4 filings
The increase was primarily driven by foreign exchange impacts of $3.2 million, unfavorable margin mix of $2.9 million, inflation of $2.1 million, and costs associated with the recent acquisitions of $22.5 million.
10-Q · Apr 29, 2026
Pricing and mixpositive · 4 filings
Medical Unaudited (In millions) Three Months Ended March 31, 2026 Three Months Ended March 31, 2025 Revenues $ 72.1 $ 68.6 Income from operations $ 7.8 $ 6.7 Income from operations as a % of revenues 10.8 % 9.8 % 49 Table of Content s Medical segment revenues…
10-Q · Apr 29, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 4.5× · EV/sales 4.5×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

15.84-4.8% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for MIR. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for MIR. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind MIR

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AMEAMETEK, Inc.competitorFeb 19, 2026

We believe the primary competitors in each of our segments are as follows: • Nuclear & Safety: Thermo Fisher Scientific, Curtiss-Wright, Ortec (Ametek), FLIR (Teledyne), Ludlum, Fuji Electric, Caen System, Fluke (Fortive), Berthold Technologies and Framatome…

FTVFortive CorporationcompetitorFeb 19, 2026

We believe the primary competitors in each of our segments are as follows: • Nuclear & Safety: Thermo Fisher Scientific, Curtiss-Wright, Ortec (Ametek), FLIR (Teledyne), Ludlum, Fuji Electric, Caen System, Fluke (Fortive), Berthold Technologies and Framatome…

Depended on by

SMRNuScale Power CorporationsupplierFeb 26, 2026

Other key suppliers include Framatome (fuel assemblies), Honeywell International Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

MIR is currently a Leader in the organic co-movement group Radiation Detection & Safety. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for MIR; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.